However, multiple recent studies have reported PRLR protein expression in ER+, HER2+ and triple negative (TNBC) breast cancers, in sharp contrast to the epidemiologic link between PRL and development of only ER+ breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.